NPS, AstraZeneca end six-year agreement on CNS disorder research

10/10/2007 | CNNMoney

NPS Pharmaceuticals and AstraZeneca have ended a research partnership to develop central nervous system disorder treatments that target metabotropic glutamate receptors. AstraZeneca will pay NPS $30 million to acquire assets related to their work.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD